English

CS MEDICA Announces Postponement of Financial Reporting Deadlines

Report this content

Postponement of Financial Reporting Deadlines Amid Key Regulatory and IPO Preparations - Q4 Interim Report Rescheduled for November 30, 2024.

At the November 12 board meeting, CS MEDICA's board resolved to postpone the financial reporting deadlines. This decision supports our commitment to providing thorough financial disclosures and managing the IPO process for our subsidiary, CANNORDIC A/S, facilitating the necessary capital increase. Additionally, the ongoing transition to comply with Medical Device Regulation (MDR) and the upcoming third audit by our notified body this November add to our substantial workload. This extension will enable us to deliver more comprehensive financial insights.

The new deadlines for our financial reports are as follows:

  • November 30, 2024 – Q4: Interim Report for July–September 2024
  • January 17, 2025 – Annual Report for 2023/2024
  • January 31, 2025 – Annual General Meeting for 2023/2024


 

For more information about CS MEDICA, please contact:
Gitte Lund Henriksen, CFO
Phone: + (45) 2774 2280
Email: glh@cs-medica.com
Website: https://www.cs-medica.com/
 

CS MEDICA A/S, a Danish MedTech pioneer, specializes in developing evidence-based, CBD-integrated treatments for pain management, autoimmune and stress-related disorders. With a focus on patient-centric care, our products range from innovative R&D to registered over-the-counter substance-based medical devices and dermaceuticals. Our flagship CANNASEN® brand, alongside our own-label solutions, exemplifies our dedication to safe, high-quality treatments for both human and veterinary health globally. The company is listed on Spotlight Stock Market in Stockholm (symbol: “CSMED”). For more information, visit cs-medica.com and LinkedIn.

Subscribe